CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
Toshikazu Moriwaki, Masahiko Gosho, Akinori Sugaya, Takeshi Yamada, Yoshiyuki Yamamoto, Ichinosuke Hyodo
Cancer Research and Treatment. 2021;53(3):703-713.   Published online 2020 December 1    DOI: https://doi.org/10.4143/crt.2020.805

Excel Download

Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
Cancer Research and Treatment. 2021;53(3):703-713   Crossref logo
Link1 Link2 Link3

187P Optimal treatment strategy of first-line oxaliplatin (Oxa)- containing therapy in metastatic colorectal cancer (mCRC): A trial-level meta-analysis
Annals of Oncology. 2016;27:ix58-ix59   Crossref logo
Link1 Link2

Retrospective Analysis of S-1 plus Bevacizumab as Maintenance Therapy after Induction of S-1 and Oxaliplatin (SOX) plus Bevacizumab as First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer
Journal of Cancer Therapy. 2020;11(02):35-43   Crossref logo
Link1 Link2

Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy
Clinical Colorectal Cancer. 2017;16(4):386-396.e1   Crossref logo
Link1 Link2

Selection of Second-line Anti-angiogenic Agents After Failure of Bevacizumab-containing First-line Chemotherapy in Metastatic Colorectal Cancer
Clinical Colorectal Cancer. 2018;17(4):251-254   Crossref logo
Link1 Link2

Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community Setting
Supportive Cancer Therapy. 2007;4(4):233-240   Crossref logo
Link1 Link2

A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer
Clinical Colorectal Cancer. 2006;5(5):363-367   Crossref logo
Link1 Link2

Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis
Clinical Colorectal Cancer. 2016;15(2):e29-e39   Crossref logo
Link1 Link2

Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
Current Colorectal Cancer Reports. 2020;16(4):89-95   Crossref logo
Link1 Link2 Link3

Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials
. 2020;   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.